[go: up one dir, main page]

MX2013008005A - Combinacion de analogos de glucagon acilados con analogos de insulina. - Google Patents

Combinacion de analogos de glucagon acilados con analogos de insulina.

Info

Publication number
MX2013008005A
MX2013008005A MX2013008005A MX2013008005A MX2013008005A MX 2013008005 A MX2013008005 A MX 2013008005A MX 2013008005 A MX2013008005 A MX 2013008005A MX 2013008005 A MX2013008005 A MX 2013008005A MX 2013008005 A MX2013008005 A MX 2013008005A
Authority
MX
Mexico
Prior art keywords
analogues
combination
acylated glucagon
insulin
analogue
Prior art date
Application number
MX2013008005A
Other languages
English (en)
Inventor
Ditte Riber
Keld Fosgerau
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45607302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013008005(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of MX2013008005A publication Critical patent/MX2013008005A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a procedimientos para tratar trastornos metabólicos, incluyendo diabetes, usando una combinación de un análogo de glucagón acilado y un análogo de insulina. La invención también presenta un kit que incluye un análogo de glucagón acilado y un análogo de insulina.
MX2013008005A 2011-01-20 2012-01-20 Combinacion de analogos de glucagon acilados con analogos de insulina. MX2013008005A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161434698P 2011-01-20 2011-01-20
PCT/IB2012/000134 WO2012098462A1 (en) 2011-01-20 2012-01-20 Combination of acylated glucagon analogues with insulin analogues

Publications (1)

Publication Number Publication Date
MX2013008005A true MX2013008005A (es) 2013-08-21

Family

ID=45607302

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008005A MX2013008005A (es) 2011-01-20 2012-01-20 Combinacion de analogos de glucagon acilados con analogos de insulina.

Country Status (21)

Country Link
US (2) US20140011733A1 (es)
EP (1) EP2665487A1 (es)
JP (1) JP2014504597A (es)
KR (1) KR20140043709A (es)
CN (1) CN103491975B (es)
AR (1) AR085086A1 (es)
AU (1) AU2012208349A1 (es)
BR (1) BR112013018269A2 (es)
CA (1) CA2824397A1 (es)
CL (1) CL2013002085A1 (es)
CO (1) CO6761400A2 (es)
EA (1) EA201390796A1 (es)
MA (1) MA34913B1 (es)
MX (1) MX2013008005A (es)
PE (1) PE20140969A1 (es)
PH (1) PH12013501495A1 (es)
SG (1) SG192038A1 (es)
TN (1) TN2013000251A1 (es)
TW (1) TW201247702A (es)
UY (1) UY33872A (es)
WO (1) WO2012098462A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5635530B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
KR20150116912A (ko) 2008-12-15 2015-10-16 질랜드 파마 에이/에스 글루카곤 유사체
US8680049B2 (en) 2008-12-15 2014-03-25 Zealand Pharma A/S Glucagon analogues
ES2439499T3 (es) 2008-12-15 2014-01-23 Zealand Pharma A/S Análogos de glucagón
PT2454282E (pt) 2009-07-13 2015-06-23 Zealand Pharma As Análogos de glucagão acilados
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
MA34383B1 (fr) 2010-06-24 2013-07-03 Zealand Pharma As Analogues de glucagon
WO2013041678A1 (en) 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
AR090937A1 (es) 2012-05-03 2014-12-17 Zealand Pharma As Compuestos agonista duales de gip-glp-1 y metodos para usarlos
BR112015001451B1 (pt) 2012-07-23 2022-03-29 Zealand Pharma A/S Composto, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um composto ou de seu sal ou solvato farmaceuticamente aceitável
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
RU2683039C2 (ru) 2013-04-18 2019-03-26 Ново Нордиск А/С Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения
US9988429B2 (en) * 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
MX368436B (es) 2013-10-17 2019-10-03 Zealand Pharma As Analogos de glucagon acilados.
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
MX369656B (es) 2014-01-20 2019-11-15 Hanmi Pharm Ind Co Ltd Insulina de accion prolongada y uso de la misma.
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
JP6657230B2 (ja) 2014-09-24 2020-03-04 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション インクレチン−インスリンコンジュゲート
ES2883345T3 (es) 2014-10-29 2021-12-07 Zealand Pharma As Compuestos agonistas del GIP y métodos
PL3283507T3 (pl) 2015-04-16 2020-05-18 Zealand Pharma A/S Acylowany analog glukagonu
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
BR102015031283A2 (pt) * 2015-12-14 2018-09-18 Univ Rio De Janeiro Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento
WO2017160669A1 (en) * 2016-03-18 2017-09-21 Merck Sharp & Dohme Corp. Insulin-incretin conjugates
WO2017189342A1 (en) 2016-04-26 2017-11-02 Merck Sharp & Dohme Corp. Insulin dimer-incretin conjugates
AU2017332408B2 (en) 2016-09-23 2022-02-10 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
AU2018239037B2 (en) 2017-03-23 2022-05-26 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
KR20200078414A (ko) * 2018-12-21 2020-07-01 한미약품 주식회사 인슐린 및 글루카곤을 포함하는 약학 조성물
CA3186427A1 (en) * 2020-06-11 2021-12-16 Abvance Therapeutics Inc. Systems, devices, compositions and methods for treating diabetes
JP2024543441A (ja) * 2021-11-19 2024-11-21 メッドシャイン ディスカバリー インコーポレイテッド ステープルペプチド及びその使用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DE69428134T2 (de) 1993-09-17 2002-05-02 Novo Nordisk A/S, Bagsvaerd Acyliertes insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
ATE290014T1 (de) 1996-09-09 2005-03-15 Zealand Pharma As Festphasen-peptidsynthese
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
HUP0200297A3 (en) 1999-03-17 2002-09-30 Novo Nordisk As Method for acylating peptides and the glutaminic acid derivatives as acylating agents
AU2002346491A1 (en) 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
EP1545460A4 (en) 2001-12-20 2005-11-16 Lilly Co Eli INSULIN MOLECULE WITH TEMPORARY EFFECT
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
CA2518776A1 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
WO2006134340A2 (en) 2005-06-13 2006-12-21 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
AU2007221366B2 (en) 2006-02-22 2012-08-23 Msd Italia S.R.L. Oxyntomodulin derivatives
WO2008043033A2 (en) 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
EA017849B1 (ru) 2007-02-15 2013-03-29 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соагонисты глюкагоновых/glp-1-рецепторов
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
KR101656107B1 (ko) 2007-11-20 2016-09-08 암브룩스, 인코포레이티드 변형된 인슐린 폴리펩티드 및 이의 용도
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
AU2009203809B2 (en) 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
CN101970476B (zh) 2008-01-09 2014-08-27 塞诺菲-安万特德国有限公司 具有超延迟时效特征的胰岛素衍生物
WO2009129250A2 (en) 2008-04-14 2009-10-22 Case Western Reserve University Meal-time insulin analogues of enhanced stability
NZ588857A (en) 2008-04-22 2012-07-27 Univ Case Western Reserve Isoform-specific insulin analogue for control blood sugar levels
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
PA8830501A1 (es) * 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
MX2011001181A (es) 2008-07-31 2011-04-05 Univ Case Western Reserve Insulina estabilizada con halogeno.
US8680049B2 (en) * 2008-12-15 2014-03-25 Zealand Pharma A/S Glucagon analogues
ES2439499T3 (es) * 2008-12-15 2014-01-23 Zealand Pharma A/S Análogos de glucagón
KR20150116912A (ko) * 2008-12-15 2015-10-16 질랜드 파마 에이/에스 글루카곤 유사체
JP5635530B2 (ja) * 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
US8481485B2 (en) 2008-12-19 2013-07-09 Indiana University Research And Technology Corporation Insulin analogs
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
CN101519446A (zh) 2009-03-31 2009-09-02 上海一就生物医药有限公司 一种重组人胰岛素及其类似物的制备方法
PT2454282E (pt) * 2009-07-13 2015-06-23 Zealand Pharma As Análogos de glucagão acilados
BR112012027759A2 (pt) * 2010-04-27 2017-08-15 Zealand Pharma As Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
AR081975A1 (es) * 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon

Also Published As

Publication number Publication date
NZ612719A (en) 2015-05-29
TN2013000251A1 (en) 2014-11-10
CA2824397A1 (en) 2012-07-26
CN103491975A (zh) 2014-01-01
CO6761400A2 (es) 2013-09-30
SG192038A1 (en) 2013-08-30
EP2665487A1 (en) 2013-11-27
US20160000883A1 (en) 2016-01-07
US20140011733A1 (en) 2014-01-09
PE20140969A1 (es) 2014-07-24
AU2012208349A1 (en) 2013-07-18
CL2013002085A1 (es) 2013-12-06
UY33872A (es) 2012-08-31
JP2014504597A (ja) 2014-02-24
KR20140043709A (ko) 2014-04-10
BR112013018269A2 (pt) 2017-06-06
AR085086A1 (es) 2013-09-11
PH12013501495A1 (en) 2013-09-16
MA34913B1 (fr) 2014-02-01
TW201247702A (en) 2012-12-01
EA201390796A1 (ru) 2014-07-30
WO2012098462A1 (en) 2012-07-26
CN103491975B (zh) 2016-05-11

Similar Documents

Publication Publication Date Title
TN2013000251A1 (en) Combination of acylated glucagon analogues with insulin analogues
MY164536A (en) Syringe
IL230611A0 (en) Solution for injection of at least one type of basal insulin
PH12016500675A1 (en) Acylated glucagon analogues
MX2016005556A (es) Compuestos agonistas duales de gip-glp-1 y procedimientos.
PH12015500531A1 (en) Glucagon analogues
MX368435B (es) Analogos del glucagon.
LT2916860T (lt) Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą
MX2014015423A (es) Analogos de peptido de exedina-4.
MX2016005560A (es) Compuestos agonistas triples de glucagon-glp-1-gip.
GB2518052B (en) Group server performance correction via actions to server subset
GB2522561B (en) Apparatus for enriching a bio-fluid with respect to the concentration of alpha-2-macroglobulin
ZA201306514B (en) Novel glucagon analogues
HRP20170209T1 (hr) Liksisenatid kao dodatna terapija uz bazalni inzulin kod dijabetesa tipa 2
MX2014002159A (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
AU2012240388A8 (en) Treatment regimens
AU2013298343A8 (en) Targeted oesophageal administration of Zn-alpha2-glycoproteins (ZAG), methods and formulations thereof
MX2014006990A (es) Tratamiento para diabetes tipo i y tipo ii.
MY151659A (en) Photopolymerizable Resin Composition
MY184721A (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
AU335165S (en) Analogue clock
EP2771019A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DIABETES AND OTHER DEGENERATIVE NEUROENDOCRINE DISEASES OR DISORDERS
HK1190319A (en) Combination of acylated glucagon analogues with insulin analogues
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
GB201201826D0 (en) Methods and compositions for treating disorders associated with impaired insulin sensitivity

Legal Events

Date Code Title Description
FA Abandonment or withdrawal